CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ensure weight-loss jabs like Ozempic, Wegovy, and Mounjaro only go to those ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...